6 Results for "

PDBu

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "PDBu" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18985
CAS No.: 37558-16-0
Synonyms: Phorbol dibutyrate; PDBu
Target:  

PKC

Research Areas:  

Cancer

Phorbol 12,13-dibutyrate (Phorbol dibutyrate) is a PKC activator and a potent skin tumor promoter .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13772
CAS No.: 56124-62-0
Purity:  99.60%
Synonyms: AD-32
Target:  

PKC Antibiotic

Research Areas:  

Inflammation/Immunology Cancer

Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.
loading...
    loading...
Cat. No.: HY-18985G
CAS No.: 37558-16-0
Synonyms: Phorbol dibutyrate (GMP); PDBu (GMP)
Phorbol 12,13-dibutyrate (Phorbol dibutyrate) (GMP) is Phorbol 12,13-dibutyrate (HY-18985) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Phorbol 12,13-dibutyrate is a PKC activator and a potent skin tumor promoter .
loading...
    loading...
Cat. No.: HY-116060
CAS No.: 140429-37-4
Research Areas:  

Infection

RK-286D is an antibiotic and a PKC inhibitor with antimicrobial activity. RK-286D shows inhibitory activities against bleb formation induced by PDBu (HY-18985) and in vitro PKC activity .
loading...
    loading...
Cat. No.: HY-13772R
CAS No.: 56124-62-0
Synonyms: AD-32 (Standard)
Valrubicin (Standard) is the analytical standard of Valrubicin. This product is intended for research and analytical applications. Valrubicin is a chemotherapy agent, inhibits TPA-and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.
loading...
    loading...
Cat. No.: HY-117578
CAS No.: 131916-69-3
Target:  

Endogenous Metabolite

Research Areas:  

Neurological Disease

KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia .
loading...
    loading...